These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 18632651)

  • 21. Cell- and peptide-based immunotherapeutic approaches for glioma.
    Yamanaka R
    Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
    Soleimani A; Berntsen A; Svane IM; Pedersen AE
    Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
    Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
    Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme.
    Briceño E; Calderon A; Sotelo J
    Surg Neurol; 2007 Apr; 67(4):388-91. PubMed ID: 17350410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?
    Van Gool S; De Vleeschouwer S
    Expert Rev Neurother; 2012 Oct; 12(10):1173-6. PubMed ID: 23082731
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.
    Phuphanich S; Wheeler CJ; Rudnick JD; Mazer M; Wang H; Nuño MA; Richardson JE; Fan X; Ji J; Chu RM; Bender JG; Hawkins ES; Patil CG; Black KL; Yu JS
    Cancer Immunol Immunother; 2013 Jan; 62(1):125-35. PubMed ID: 22847020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme.
    Struss AK; Romeike BF; Munnia A; Nastainczyk W; Steudel WI; König J; Ohgaki H; Feiden W; Fischer U; Meese E
    Oncogene; 2001 Jul; 20(31):4107-14. PubMed ID: 11464277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.
    Wang LF; Fokas E; Bieker M; Rose F; Rexin P; Zhu Y; Pagenstecher A; Engenhart-Cabillic R; An HX
    Oncol Rep; 2008 Jan; 19(1):151-6. PubMed ID: 18097589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
    Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
    Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DCVax®-L--developed by Northwest Biotherapeutics.
    Polyzoidis S; Ashkan K
    Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccines for glioblastoma and high-grade glioma.
    Wheeler CJ; Black KL
    Expert Rev Vaccines; 2011 Jun; 10(6):875-86. PubMed ID: 21692706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.
    Morita S; Oka Y; Tsuboi A; Kawakami M; Maruno M; Izumoto S; Osaki T; Taguchi T; Ueda T; Myoui A; Nishida S; Shirakata T; Ohno S; Oji Y; Aozasa K; Hatazawa J; Udaka K; Yoshikawa H; Yoshimine T; Noguchi S; Kawase I; Nakatsuka S; Sugiyama H; Sakamoto J
    Jpn J Clin Oncol; 2006 Apr; 36(4):231-6. PubMed ID: 16611662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients.
    Victora GD; Socorro-Silva A; Volsi EC; Abdallah K; Lima FD; Smith RB; Moyses RA; Zárate-Bladés CR; Michaluart P; Silva CL; Kalil J; Coelho V
    Cancer Gene Ther; 2009 Jul; 16(7):598-608. PubMed ID: 19197326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
    Batich KA; Swartz AM; Sampson JH
    Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glioblastoma-derived mechanisms of systemic immunosuppression.
    Waziri A
    Neurosurg Clin N Am; 2010 Jan; 21(1):31-42. PubMed ID: 19944964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.
    Walker DG; Laherty R; Tomlinson FH; Chuah T; Schmidt C
    J Clin Neurosci; 2008 Feb; 15(2):114-21. PubMed ID: 18083572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I clinical trial of a TGF-beta antisense-modified tumor cell vaccine in patients with advanced glioma.
    Fakhrai H; Mantil JC; Liu L; Nicholson GL; Murphy-Satter CS; Ruppert J; Shawler DL
    Cancer Gene Ther; 2006 Dec; 13(12):1052-60. PubMed ID: 16826191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.